Navigation Links
Molecular imaging detects recurrent prostate cancer
Date:6/6/2010

SALT LAKE CITYFindings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.

"Despite definitive treatment, about 30 percent of prostate cancers recur," said David Schuster, M.D., director of the division of nuclear medicine and molecular imaging and assistant professor of radiology at Emory University School of Medicine, Atlanta, Ga. "This troubling statistic led our research team to diligently work on developing new techniques to more effectively detect and diagnose recurrent prostate tumors and associated cancers that have spread to nearby tissues and organs."

According to the authors, a radiotracer known as anti-18F-FACBC could be used to effectively and non-invasively detect and differentiate tumors recurring in the prostate and metastatic cancers that develop, most notably in the surrounding lymph nodes. "This may lead to custom-tailored treatments for prostate cancer patients that cater to their specific tumor type and progression of disease," added Schuster.

The new imaging agent, developed by Dr. Mark Goodman at Emory University, consists of a fluorine-based radioisotope paired with a synthetic amino-acid analog similar to the naturally-occurring amino acid L-leucine. Amino acids are essentially the building blocks of protein, and many cells have a system that controls the transport of amino acids into the cell in order to facilitate the production of new proteins. Upon injection, anti-18F-FACBC is absorbed by various cells by this transport system, but the "uptake," or admission of the agent, is much higher in aggressively multiplying cancer cells, which need more of these proteins in order to proliferate.

Researchers scanned 83 patients suspected of having recurrent prostate cancer using a hybrid positron emission tomography and computed tomography (PET/CT) system, a molecular imaging technique that displays both anatomical information and physiological processes in the body. Resulting scans were evaluated to determine the presence of recurrent prostate tumors and outlying tumors that had metastasized, or spread, to other tissues, including those of nearby bones and lymph nodes that tend be to a target for cancer metastases. The agent was able to positively identify recurrent carcinomas in the prostate region with 74-percent accuracy, and metastatic cancers with 96-percent accuracy, catching even small tumors within lymph nodes that other imaging agents could not detect. The ability to differentiate tumors recurring in the prostate from metastatic cancers with high accuracy is the most promising aspect of this PET radiotracer.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Molecular Signatures in Post-Mortem Brain Tissue of Younger Individuals at High Risk for Alzheimer's Disease
2. Molecular imaging and CT colonography team up to bring comfort to patients
3. Acupunctures molecular effects pinned down
4. Salt Lake City proclaims Molecular Imaging Days during SNMs Annual Meeting in June
5. Scientists discover the molecular heart of collective behavior
6. News from Molecular Medicine
7. Molecular marker could help spot pancreatic cancer early
8. Molecular discovery points to new therapies for brain tumors
9. USC researchers discover new molecular subtype of brain cancer
10. The Association for Molecular Pathology celebrates ruling in DNA patent case
11. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... The International Vaccine Institute (IVI) and ... the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine ... deployment in the event of a future outbreak. , IVI and GeneOne held ...
(Date:12/6/2016)... ... 2016 , ... According to a November 1 article published on ... or not drinking enough water, which can cause bad breath (known medically as halitosis). ... oral hygiene not only helps reduce the possibility of bad breath, but it can ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... for population health management, announces today a strategic relationship with CitiusTech, a ... clinical rules engine that offers advanced Clinical Quality Measures (CQM) computation capabilities ...
(Date:12/6/2016)... ... December 06, 2016 , ... In anticipation for the New Year, ... availability of continuing education courses in 2017, dentists of all levels can continue to ... in January, dentists can attend a variety of continuing education courses each month on ...
(Date:12/6/2016)... ... ... Why does the prevalence of obesity continue to increase worldwide? Some would say ... the cause of obesity in his new book “Body Weight Regulation.” , “Body ... a healthy life. Proietto said understanding the regulation of body weight and the causes ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Inc. (NASDAQ: IONS ), the leader in antisense therapeutics, ... BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December ... A live webcast of the presentation will be available on the ... be available within 48 hours and will be archived for a ... , , ...
(Date:12/7/2016)... YORK , December 7, 2016 ... Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals Inc. ... DNAI ), and AveXis Inc. (NASDAQ: AVXS ... Sector Index fell roughly 37% to reach a level equal ... it is down by approximately 14% for the year, it ...
(Date:12/7/2016)... 2016 According to the latest ... Market Study on Multiplex Detection Immunoassay: North America to ... global multiplex detection immunoassay market is expected to witness a CAGR ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
Breaking Medicine Technology: